STTK Shattuck Labs, Inc.
Price Chart
Executive Summary
Shattuck Labs priced a public offering of 10,879,376 common shares at $4.00/share and pre-funded warrants for 7,870,624 shares at $3.9999/warrant, expecting ~$75M in gross proceeds. The offering closes June 11, 2026, with underwriters having a 30-day option for an additional 2,812,500 shares. This dilutive capital raise provides cash runway for a clinical-stage biotech with no approved products, signaling near-term financing needs.
Key Financial Metrics
Actionable Insight
The $75M raise provides cash runway for clinical development but at a 21% discount to the prior close (assuming $4.00 vs. $5.07 pre-announcement). Monitor for potential further dilution if the underwriters' option is exercised. The stock may face continued pressure as the market absorbs the new shares. Watch for pipeline updates on SL-325 as the primary catalyst for future value.
Key Facts
- Offering of 10,879,376 common shares at $4.00/share and pre-funded warrants for 7,870,624 shares at $3.9999/warrant.
- Expected aggregate gross proceeds of approximately $75 million.
- Underwriters have a 30-day option to purchase up to an additional 2,812,500 shares.
- Offering expected to close on June 11, 2026.
- Pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable.
- Shattuck Labs is a clinical-stage biotech with no approved products, focused on DR3 blocking antibodies for inflammatory diseases.
Financial Impact
Approximately $75 million gross proceeds from the offering, representing significant dilution to existing shareholders. Based on the $4.00 offering price and pre-offering market cap of ~$299M, the new shares (excluding the underwriters' option) represent roughly 18.7% dilution (10.88M new shares vs. ~74.75M pre-offering shares, estimated from market cap/price).
Risk Factors
- Dilution of approximately 18.7% from the offering (excluding underwriters' option), which could further increase if the option is exercised.
- Clinical-stage biotech with no approved products; reliance on successful development of SL-325.
- Potential for additional capital raises in the future given the cash-intensive nature of clinical trials.
- Underwriters' option for up to 2,812,500 additional shares could add further dilution.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309437 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 11, 2026
4d ago
|
424B5
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (−15.69%) |
|
Jun 9, 2026
5d ago
|
424B5
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (−15.69%) |
|
Jun 9, 2026
5d ago
|
8-K
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (+15.69%) |
|
Jun 2, 2026
12d ago
|
8-K
| $4.75 $4.80 | ▲ +1.05% | ▲ +0.65% | $4.94 (+4.00%) |
|
May 15, 2026
4w ago
|
Insider Cluster
| $6.26 $5.97 | ▼ −4.63% | ▼ −4.57% | $4.94 (−21.09%) |
|
May 12, 2026
4w ago
|
Insider Cluster
| $6.62 $6.75 | ▲ +1.96% | ▲ +1.39% | $4.94 (−25.38%) |
|
May 7, 2026
5w ago
|
8-K
| $6.26 $6.85 | ▲ +9.42% | ▲ +8.59% | $4.94 (−21.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access